MARCY L'ETOILE, France & SAN CARLOS, Calif.--(BUSINESS WIRE)--Regulatory News:
bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, and NuGEN Technologies, Inc., a privately held company that develops and commercializes nucleic acid amplification and labelling systems, announced today an agreement to cross-license intellectual property, as well as a supply agreement for NuGEN's exclusive WT-Ovation RNA Amplification System.
